secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001104659-22-086903
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q2 revenue $1.177B down 8%; cuts full-year guidance on macro headwinds
-----------------------------------------------------------------------------

- Q2 revenue $1,177M (-8% reported, -4% constant currency); Pet Health $612M (-11%), Farm Animal $553M (-2%).
- Reported EPS $(0.04), adjusted EPS $0.36; adjusted EBITDA $300M (25.5% margin) vs $291M prior year.
- Full-year revenue guidance cut to $4,465-$4,550M from $4,700-$4,755M; adjusted EPS now $1.06-$1.13 vs $1.15-$1.21.
- Net leverage 5.3x; target ~5.0x by year-end; 60% gross margin and 31% adjusted EBITDA timeline extended.
- In-licensed feline diabetes product under FDA review; Zorbium launched; pipeline on track for two blockbuster submissions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922086903/0001104659-22-086903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465922086903/tm2222756d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-086903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer